Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Transfer of iNKT Cells for Relapsed/Advanced HCC
NCT03175679Phase 1Completed
- Sponsor
- Beijing YouAn Hospital
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial in hepatocellular carcinoma (HCC) (4 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Number of Adverse Events at 20 months. Started Apr 2017; status: completed.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03175679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175679.